• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Longeveron Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    3/14/25 4:02:25 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email
    false 0001721484 0001721484 2025-03-13 2025-03-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of
    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 13, 2025

     

    Longeveron Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40060   47-2174146

    (State or other jurisdiction

    of incorporation)

      (Commission File Number)  

    (IRS Employer

    Identification No.)

     

    1951 NW 7th Avenue, Suite 520

    Miami, Florida 33136

    (Address of principal executive offices)

     

    Registrant’s Telephone Number, Including Area Code: (305) 909-0840

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)  

    Name of each exchange

    on which registered

    Class A Common Stock, $0.001 par value per share   LGVN   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Section 4- Matters Related to Accountants and Financial Statements

     

    Item 4.01 Changes in Registrant’s Certifying Accountant.

     

    (a) Resignation of Independent Registered Public Accounting Firm

     

    On March 13, 2025, Longeveron Inc. (the “Company”) was notified by Marcum LLP (“Marcum”) that Marcum resigned as the Company’s independent registered public accounting firm. On November 1, 2024, CBIZ CPAs P.C. (“CBIZ”) acquired the attest business of Marcum. Substantially all of the partners and staff that provided attestation services with Marcum joined CBIZ. On March 13, 2025, Marcum resigned as auditors of the Company, and the Company’s Audit Committee and Board of Directors approved the resignation.

     

    The report of Marcum on the Company’s financial statements for the fiscal years ended December 31, 2024 and 2023 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, did not contain an adverse opinion or a disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principle, except for the inclusion of an explanatory paragraph in the audit reports for the fiscal years ended December 31, 2024 and 2023 as to the Company’s ability to continue as a going concern.

     

    During the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through March 13, 2025, there were no (1) disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) between the Company and Marcum on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which would have caused it to make reference to the subject matter of such a disagreement in connection with its audit reports on the Company’s financial statements for such years, or (2) reportable events (as described in Item 304(a)(1)(v) of Regulation S-K).

     

    The Company has provided Marcum with a copy of the foregoing disclosures it is making in this Current Report on Form 8-K prior to its filing and requested, in accordance with applicable practices, that Marcum furnish a letter addressed to the Securities and Exchange Commission (“SEC”) stating whether or not it agrees with the statements made herein. Attached as Exhibit 16.1 is a copy of Marcum’s letter, dated March 14, 2025, stating that it agrees with such statements.

     

    (b) Engagement of New Independent Registered Public Accounting Firm

     

    On March 13, 2025, with the approval of the Company’s Audit Committee and Board of Directors, CBIZ was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.

     

    During the fiscal years ended December 31, 2024 and 2023 and through March 13, 2025, neither the Company nor anyone on its behalf consulted with CBIZ regarding (1) the application of accounting principles to a specified transaction, completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements, and neither a written report nor oral advice was provided to the Company that CBIZ concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue, or (2) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a reportable event (as described in Item 304(a)(1)(v) of Regulation S-K). 

     

    1 

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    The exhibit listed in the following Exhibit Index is filed as part of this Current Report on Form 8-K.

     

    Exhibit No.   Description
    16.1   Letter to Securities and Exchange Commission from Marcum LLP dated March 14, 2025
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      LONGEVERON INC.
       
    Date: March 14, 2025 /s/ Wa’el Hashad
      Name: Wa’el Hashad  
      Title: Chief Executive Officer

     

     

    3

     

    Get the next $LGVN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $LGVN

    DatePrice TargetRatingAnalyst
    12/6/2024$10.00Buy
    ROTH MKM
    1/5/2022$20.00Buy
    EF Hutton
    More analyst ratings

    $LGVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Hashad Mohamed Wa'El Ahmed covered exercise/tax liability with 13,146 shares, decreasing direct ownership by 5% to 240,904 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      7/3/25 6:00:14 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Hare Joshua

      4 - Longeveron Inc. (0001721484) (Issuer)

      7/3/25 6:00:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CTO & SVP of CMC Blass Devin covered exercise/tax liability with 4,599 shares, decreasing direct ownership by 4% to 116,485 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      7/3/25 6:00:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    SEC Filings

    See more
    • SEC Form S-8 filed by Longeveron Inc.

      S-8 - Longeveron Inc. (0001721484) (Filer)

      6/20/25 4:25:28 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Longeveron Inc. (0001721484) (Filer)

      6/16/25 4:01:25 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Longeveron Inc.

      144 - Longeveron Inc. (0001721484) (Subject)

      5/15/25 3:20:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Longeveron® Appoints Than Powell as Chief Business Officer

      Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

      6/26/25 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

      Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II results are positiveU.S. FDA has awarded laromestrocel HLHS program Rare Pediatric Disease designation, Orphan drug designation, and Fast track designationLaromestrocel HLHS program addresses unmet medical needs with U.S. market potential of up to $1 billion MIAMI, June 24, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic a

      6/24/25 6:30:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

      MIAMI, June 09, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa'el Hashad, CEO, will present at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, taking place June 16-17, 2025. Details for the Company's corporate presentation: Pre-recorded presentation available on-demand Monday, June 16, at 7:00 a.m. ETLongeveron presentation webcast link: Click Here The webcast for this conference presentation may be accessed at the "Events and Presentations" section of the Company's website. A replay of

      6/9/25 9:15:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $LGVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Longeveron with a new price target

      ROTH MKM initiated coverage of Longeveron with a rating of Buy and set a new price target of $10.00

      12/6/24 7:54:21 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EF Hutton initiated coverage on Longeveron with a new price target

      EF Hutton initiated coverage of Longeveron with a rating of Buy and set a new price target of $20.00

      1/5/22 10:22:40 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hare Joshua bought $350,000 worth of shares (148,936 units at $2.35), increasing direct ownership by 31% to 633,280 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:29 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hashad Mohamed Wa'El Ahmed bought $24,999 worth of shares (10,638 units at $2.35), increasing direct ownership by 118% to 19,616 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:23 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Soffer Rock bought $325,000 worth of shares (138,298 units at $2.35), increasing direct ownership by 197% to 208,534 units (SEC Form 4)

      4 - Longeveron Inc. (0001721484) (Issuer)

      4/12/24 7:00:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Leadership Updates

    Live Leadership Updates

    See more
    • Longeveron® Appoints Than Powell as Chief Business Officer

      Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Than Powell as Chief Business Officer, effective July 7, 2025. In this role, he will lead the Company's overall business strategy, Alzheimer's disease program partnering efforts, and international strategy for the hypoplastic left heart syndrome (HLHS) program. "We are delighted to have Than join Longeveron at this transformational time in the Company's

      6/26/25 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)

      MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company's technological and manufacturing strategies. "We are delighted to have Devin join Longeveron at this transformational time in the Company's evolution," said Wa'el Hashad, Chief Executive Officer at Longeveron. "This appointment reinforces Longevero

      11/11/24 9:05:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Neha Motwani Elected to Longeveron® Board of Directors

      MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer's disease, today announced that Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors at the Company's recent Annual Meeting of Stockholders. "I am delighted to welcome Neha, with her tremendous healthcare industry experience, to the Board of Directors," said Joshua Hare, Co-founder, Chief Science Officer and Chairman of the Board at Longeveron. "Her exte

      7/9/24 9:00:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Financials

    Live finance-specific insights

    See more
    • Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer's disease were published in Nature MedicinePositive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer's disease; single, pivotal Phase 2/3 adaptive design clinica

      5/8/25 4:05:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

      MIAMI, May 02, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report first quarter 2025 financial results and provide a business update on Thursday, May 8, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Webcast Details:      Conference Call Number:    1.877.407.0789 Conference ID:    13752361     Call meTM Feature:  Click HereWebcast:  Click Here     An archived replay of the webcast will be available o

      5/2/25 8:30:00 AM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update

      Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development paths for Lomecel-B™ in mild Alzheimer's diseaseWHO International Nonproprietary Names (INN) Expert Committee approved "laromestrocel" for the non-proprietary name of Lomecel-B™Total Revenue

      2/28/25 4:04:00 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LGVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Longeveron Inc.

      SC 13G/A - Longeveron Inc. (0001721484) (Subject)

      11/14/24 4:20:18 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      7/26/24 4:18:08 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Longeveron Inc.

      SC 13G - Longeveron Inc. (0001721484) (Subject)

      4/17/24 4:03:33 PM ET
      $LGVN
      Biotechnology: Pharmaceutical Preparations
      Health Care